Baseline characteristics of all patients
| N | % or mean (SD) | |
| Age (years) | 211 | 56.4 (13.7) |
| Male | 201/211 | 95.3% |
| Caucasian | 183/202 | 90.6% |
| Disease duration (years) | 204 | 7.8 (7.6) |
| College education | 118/206 | 57.3% |
| Married/cohabiting | 155/208 | 74.5% |
| Working | 133/208 | 63.9% |
| Body mass index (kg/m2) | 211 | 28.8 (4.5) |
| Comorbidities (SCQ sum) | 210 | 3.7 (3.2) |
| Physical activity >3 times weekly | 163/207 | 30.4% |
| Smoking, daily | 23/208 | 11.1% |
| Alcohol consumption | 207 | |
| Daily | 17 | 8.2% |
| Weekly | 111 | 53.6% |
| Monthly | 55 | 26.6% |
| Never | 24 | 11.6% |
| Sugar sweetened drinks consumed daily | 80/207 | 38.6% |
| Tophus present (>1) | 35/211 | 16.6% |
| No. tophi | 211 | |
| 0 | 176 | 83.4% |
| 1–5 | 30 | 14.2% |
| >5 | 5 | 2.4% |
| Allopurinol use ever | 31/211 | 14.7% |
| NSAID use ever | 160/205 | 78.0% |
| Colchicine use ever | 107/201 | 53.2% |
| Prednisolone use ever | 91/199 | 45.7% |
| Baseline sUA (µmol/L) | 211 | 500 (77) |
| ESR (mm/hour) | 199 | 14.5 (14.2) |
| Creatinine (µmol/L) | 211 | 96.3 (18.6) |
| eGFR (mL/min per 1.73 m2) | 210 | 78 (19) |
| No. flares before recent one | 208 | |
| None | 16 | 7.7% |
| 1 | 25 | 12.0% |
| 2–5 | 65 | 31.3% |
| >5 | 102 | 49.0% |
| Other flare experienced last 12 months before inclusion? | 151/206 | 73.4% |
| Strongest joint pain ever (0–10) | 208 | 8.4 (1.6) |
| Joint pain last flare (0–10) | 207 | 7.5 (5.5) |
| Swollen joint present | 72/209 | 34.4% |
| Tender joint present | 110/210 | 52.4% |
| Health Assessment Questionnaire (0–3) | 209 | 0.38 (0.57) |
| SF-36 physical component summary (0–100) | 204 | 39.1 (11.1) |
| SF-36 mental component summary (0–100) | 204 | 50.0 (10.2) |
| Self-efficacy pain (10–100) | 209 | 65.3 (19.5) |
| Self-efficacy symptoms (10–100) | 205 | 72.6 (15.1) |
| Beliefs about Medicines Questionnaire | ||
| Necessity subscale (5–25) | 198 | 17.9 (4.4) |
| Concerns subscale (5–25) | 197 | 13.4 (4.9) |
| Overuse subscale (4–16) | 203 | 10.6 (2.8) |
| Harm subscale (4–16) | 203 | 9.4 (2.4) |
eGFR, electronic glomerular filtration rate; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug; SCQ, Self-Administered Comorbidity Questionnaire; SF-36, Short-Form 36.